The patient underwent head computed tomography (CT) and magnetic resonance imaging (MRI) of the brain. These showed multiple, bilateral lesions with surrounding edema on fluid-attenuated inversion ...

Paramagnetic rim lesions may help assess MS risk in people with radiologically isolated syndrome before symptoms appear.

The combination of cortical lesions and central vein sign in MRI increases the specificity and sensitivity for diagnosing multiple sclerosis. This study suggests that CLs and CVS, when used together, ...

Frexalimab, an investigational second-generation CD40 ligand (CD40L) inhibitor, led to fewer new gadolinium-enhancing T1-weighted lesions in relapsing multiple sclerosis (MS), a phase II trial showed.

Changes in NAWM and NAGM are crucial in MS progression, challenging the traditional lesion-centric model. Subtle alterations in myelin integrity, immune cell function, and neuronal connectivity ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase II FENopta study evaluating ...

– New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to ...

Zenas Biopharma’s autoimmune drug candidate has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study. The midstage MoonStone study saw 116 ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said its oral drug fenebrutinib met the main and secondary goals of a phase 2 trial by reducing brain lesions in adults with relapsing forms of multiple sclerosis ...

Share on Pinterest Researchers say brain lesions don’t appear to be connected to severe disability in multiple sclerosis. SeventyFour/Getty Images About 1 million people in the United States live with ...

The drug met the primary endpoint in the MoonStone trial for Relapsing Multiple Sclerosis (RMS), showing a statistically significant reduction in new gadolinium-enhancing T1 lesions, which are markers ...